SCHEMBL16748425

SCHEMBL16748425

CCc1nc2c(F)cc(F)cc2n1-c1nc(N)nc(Nc2ccc(Cl)c(F)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.36
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
CYBB P04839 1/20 0.36
NOX5 Q96PH1 1/20 0.36
NOX3 Q9HBY0 1/20 0.36
NOX4 Q9NPH5 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
TERT O14746 1/20 0.35
RAPGEF4 Q8WZA2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
MAPT P10636 1/20 0.34
XBP1 P17861 1/20 0.34
KMT2A Q03164 1/20 0.34
DHFR P00374 3/20 0.34
APP P05067 1/20 0.34
BCDIN3D Q7Z5W3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748421 0.90 AGPAT2 (0.41) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748427 0.89 MAPK1 (0.38) MAPK1AURKAAURKBFFAR1FFAR4
SCHEMBL16748446 0.89 NPC1 (0.37) MAPK1AURKAAURKBFFAR1FFAR4
SCHEMBL16748593 0.88 CYBB (0.42) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16748428 0.87 AGPAT2 (0.40) MAPK1CYBBNOX5NOX3NOX4
SCHEMBL16740864 0.85 BMI1 (0.48) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16748597 0.85 MAPT (0.44) MAPK1MEN1MAPTKMT2ATDP1
SCHEMBL16740802 0.85 BMI1 (0.40) CYBBNOX5NOX3NOX4NOX1
SCHEMBL16740735 0.84 PIK3CA (0.44) DHFRBMI1
SCHEMBL16740783 0.83 BMI1 (0.50) FFAR1MAPTDHFRHTTBMI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B MAPK1 1302/4885AURKA 4240/4885AURKB 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.